Rave O
Z Rheumatol. 1987 Mar-Apr;46(2):86-91.
Out of 160 patients with confirmed resp. classical rheumatoid arthritis, according to the ARA criteria, six patients under treatment with sulfasalazine granulocytopenias, in association with thrombocytopenia in one case, and with a decrease in erythrocytes in two cases, have been observed. Remarkably, in all six cases the relatively early hemogram alterations appear as soon as the start of therapy and prompt normalization of blood counts occurs after instant termination of sulfasalazine therapy. Possible mechanisms for the occurrence of these sulfasalazine-induced hematological complications are discussed. These observations, also described by other authors, should be a cause for more frequent blood count tests during sulfasalazine therapy, at least during the first 3 months on a weekly basis. Sulfasalazine represents an asset among the rather limited number of basic therapies available for chronic rheumatoid arthritis. Despite the fact that it is comparatively well tolerated, a close follow-up of the therapy, especially during the initial phases of treatment, is of utmost importance in order to seize upon these reversible hematological disorders at an early stage and thus avoid more serious complications.
在160例根据美国风湿病学会（ARA）标准确诊为类风湿性关节炎的患者中，观察到6例接受柳氮磺胺吡啶治疗的患者出现粒细胞减少症，其中1例伴有血小板减少症，2例伴有红细胞减少。值得注意的是，在所有6例中，相对早期的血常规改变在治疗开始后立即出现，在柳氮磺胺吡啶治疗立即终止后，血细胞计数迅速恢复正常。文中讨论了这些柳氮磺胺吡啶诱导的血液学并发症发生的可能机制。其他作者也描述过这些观察结果，这应该成为在柳氮磺胺吡啶治疗期间更频繁进行血常规检查的原因，至少在最初3个月每周检查一次。在可用于慢性类风湿性关节炎的相当有限的基础治疗方法中，柳氮磺胺吡啶是一种有用的药物。尽管它的耐受性相对较好，但对治疗进行密切随访，尤其是在治疗的初始阶段，对于早期发现这些可逆性血液系统疾病并因此避免更严重的并发症至关重要。
